Suzhou Ribo Life Science Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2019	FY 2018	FY 2017
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
Revenue	142.63	0.04	-	-	-
Revenue Growth (YoY)	324052.27%	-	-	-	-
Cost of Revenue	11.9	0.02	1.96	2.44	0.74
Gross Profit	130.72	0.02	-1.96	-2.44	-0.74
Selling, General & Admin	93.49	81.45	25.43	18.53	14.51
Research & Development	280.37	315.76	112.68	90.48	61.94
Other Operating Expenses	15.2	51.81	0.13	0.05	0.16
Operating Expenses	389.06	449.02	138.43	109.12	76.69
Operating Income	-258.34	-449	-140.39	-111.57	-77.43
Interest Expense	-20.4	-19.19	-1.95	-	-
Interest & Investment Income	-	-	1.05	2.86	3.13
Earnings From Equity Investments	-	-0.02	-	-3.89	-6.16
Currency Exchange Gain (Loss)	-	-	0.23	0.26	-1.99
Other Non Operating Income (Expenses)	21.69	31.07	-0.03	-0.02	-0.02
EBT Excluding Unusual Items	-257.05	-437.15	-141.08	-112.36	-82.46
Gain (Loss) on Sale of Assets	-	-	-0	-0.01	-0
Asset Writedown	-	-	-0.02	-0	-0
Other Unusual Items	-	-	6.44	13.1	8.66
Pretax Income	-257.05	-437.15	-134.67	-99.27	-73.8
Income Tax Expense	24.45	0.15	-	-	-
Earnings From Continuing Operations	-281.49	-437.3	-134.67	-99.27	-73.8
Minority Interest in Earnings	11.34	8.95	0.31	0.61	0.39
Net Income	-270.15	-428.35	-134.35	-98.66	-73.41
Net Income to Common	-270.15	-428.35	-134.35	-98.66	-73.41
Shares Outstanding (Basic)	129	128	30	27	24
Shares Outstanding (Diluted)	129	128	30	27	24
Shares Change (YoY)	0.31%	330.25%	10.22%	10.39%	-
EPS (Basic)	-2.10	-3.34	-4.51	-3.65	-3.00
EPS (Diluted)	-2.10	-3.34	-4.51	-3.65	-3.00
Free Cash Flow	-84.04	-327.53	-144.63	-111.39	-79.06
Free Cash Flow Per Share	-0.65	-2.55	-4.85	-4.12	-3.23
Gross Margin	91.65%	45.45%	-	-	-
Operating Margin	-181.13%	-1020454.54%	-	-	-
Profit Margin	-189.41%	-973520.46%	-	-	-
Free Cash Flow Margin	-58.92%	-744395.46%	-	-	-
EBITDA	-218.79	-405.18	-121.55	-95.33	-71.83
EBITDA Margin	-153.40%	-	-	-	-
D&A For EBITDA	39.55	43.82	18.83	16.24	5.6
EBIT	-258.34	-449	-140.39	-111.57	-77.43
EBIT Margin	-181.13%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.